Determination of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1, 5-a]quinoxalin-4(5H)-one in serum by high-performance liquid chromatography.
A high-performance liquid chromatographic assay with solid-phase extraction (SPE) for the rapid and sensitive quantitation of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1, 5-a]quinoxalin-4(5H)-one (I, U-78875) in serum is described. The validation results indicated that the present method had excellent intra- and inter-assay precision (less than or equal to 9.5%, mean +/- S.D. = 3.9 +/- 3.0%, n = 25) and accuracy (less than or equal to 10.0%, mean +/- S.D. = 3.0 +/- 2.9%, n = 25), as well as improved sensitivity (2 ng ml, using a 100-microliters injection). Each chromatographic run is only 10 min and the organic solvent for the extraction of I and internal standard (U-82217) from serum was only 300 microliters. The application results obtained from the SPE method were in good agreement with the advanced automated sample preparation method.
Zhong
W Z
WZ
Drug Metabolism Research, Upjohn Company, Kalamazoo, MI 49001.
D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004285:Dogs; D010069:Oxadiazoles / Q000097:blood* / Q000493:pharmacokinetics; D011810:Quinoxalines / Q000097:blood* / Q000493:pharmacokinetics
D010069:Oxadiazoles; D011810:Quinoxalines; C069443:panadiplon